Zai Lab Announces Acceptance of Supplemental Biologics License Application with Priority Review for Efgartigimod Alfa Injection (Subcutaneous Injection) in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China
2024年 5月 14日
Read MoreZai Lab Announces Approval of AUGTYRO™ (repotrectinib) for Patients with ROS1-positive NSCLC by China’s NMPA
2024年 5月 12日
Read MoreZai Lab Announces First Quarter 2024 Financial Results and Recent Corporate Updates
2024年 5月 08日
Read MoreZai Lab to Announce First Quarter 2024 Financial Results and Recent Corporate Updates on May 8, 2024
2024年 4月 15日
Read MoreZai Lab Statement on Executive Management Team’s Agreement on Share Activities
2024年 4月 11日
Read MoreZai Lab Presentations at AACR 2024 Annual Meeting to Showcase Ongoing Clinical Studies in Key Global Oncology Programs
2024年 4月 02日
Read MoreZai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRAS G12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
2024年 4月 01日
Read More